There is no difference between leading drugs used to combat age-related macular degeneration (AMD), according to a new study.
Research carried out by experts from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System failed to show a difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis).
In the study, which published online in Eye, patients were enrolled by a 2:1 ratio to receive either Avastin or Lucentis and given eye injections of one of the drugs every month for the first three months, followed by monthly examinations and testing.
Lead author and principal investigator Dr Manju Subramanian commented: "With the exception that total injections given to subjects over one year were significantly different between the two treatment arms, visual and anatomic outcomes at one year failed to show a significant difference between both groups."
Meanwhile, new research by the European Society of Cataract and Refractive Surgeons has found that four out of five people have reservations about having laser eye surgery, despite the majority of people in need of vision correction believing it is a safe and established procedure.
by Alexa Kaczka